S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/BVF Partners/Q1 2025

BVF Partners

Period: Q1 2025 Β· Filed: 2025-05-15
View on SEC EDGAR β†—
AUM
$2.45B
Total portfolio value
Positions
51
Reported securities
Top Holding
MLTX
31.4% $771.7M
QoQ Changes
+2 / -4
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-05-15) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
MLTXMOONLAKE IMMUNOTHERAPEUTICS$771.7M31.45%$39.07$18.95-51.5%
31.4%
AXSMAXSOME THERAPEUTICS INC$197.1M8.03%$116.63$244.31+109.5%
8.0%
RVMDREVOLUTION MEDICINES INC$176.2M7.18%$35.36$189.24+435.2%
7.2%
KYMRKYMERA THERAPEUTICS INC$141.3M5.76%$27.37$113.51+314.7%
5.8%
MIRMMIRUM PHARMACEUTICALS INC$126.0M5.13%$45.05$125.59+178.8%
5.1%
PTGXPROTAGONIST THERAPEUTICS INC$124.5M5.08%$48.36$131.62+172.2%
5.1%
GHRSGH RESEARCH PLC$97.4M3.97%$11.03$27.01+144.9%
4.0%
XOMAXOMA ROYALTY CORPORATION$59.5M2.42%$19.93$43.00+115.8%
2.4%
IONSIONIS PHARMACEUTICALS INC$57.7M2.35%$30.17$81.80+171.1%
2.4%
ZYMEZYMEWORKS INC$51.3M2.09%$11.91$26.31+120.9%
2.1%
KURAKURA ONCOLOGY INC$51.2M2.09%$6.60$11.10+68.2%
2.1%
CGEMCULLINAN THERAPEUTICS INC$43.5M1.77%$7.57$17.63+132.9%
1.8%
ACIUAC IMMUNE SA$37.1M1.51%$1.87$2.51+34.2%
1.5%
TYRATYRA BIOSCIENCES INC$36.7M1.50%$9.30$30.62+229.3%
1.5%
LKFTGALAPAGOS NV$36.5M1.49%$25.12$30.39+21.0%
1.5%
CELCCELCUITY INC$35.0M1.43%$10.11$107.95+967.8%
1.4%
VERVVERVE THERAPEUTICS INC$31.6M1.29%β€”β€”
1.3%
GPCRSTRUCTURE THERAPEUTICS INC$30.7M1.25%$17.31$53.45+208.8%
1.3%
XNCRXENCOR INC$29.2M1.19%$10.64$15.00+41.0%
1.2%
GLUEMONTE ROSA THERAPEUTICS INC$26.3M1.07%$4.64$24.21+421.8%
1.1%
SEPNSEPTERNA INC$25.4M1.04%$5.79$34.00+487.2%
1.0%
ELDNELEDON PHARMACEUTICALS INC$21.3M0.87%$3.39$3.95+16.5%
0.9%
CDTXCIDARA THERAPEUTICS INC$19.9M0.81%β€”β€”
0.8%
OLMAOLEMA PHARMACEUTICALS INC$19.9M0.81%$3.76$12.64+236.2%
0.8%
PVLAPALVELLA THERAPEUTICS INC NE$19.5M0.79%$27.99$146.76+424.3%
0.8%
FHTXFOGHORN THERAPEUTICS INC$19.4M0.79%$3.65$5.30+45.2%
0.8%
ITOSITEOS THERAPEUTICS INC$18.4M0.75%β€”β€”
0.8%
FDMT4D MOLECULAR THERAPEUTICS IN$14.7M0.60%$3.23$13.00+302.5%
0.6%
EPIXESSA PHARMA INC$13.8M0.56%β€”β€”
0.6%
ANNXANNEXON INC$13.5M0.55%$1.93$5.46+182.9%
0.6%

Quarter-on-Quarter Activity

Q1 2025 vs. Q4 2024

New Positions (2)

TickerIssuerNotionalSince Filing
IONSIONIS PHARMACEUTICALS INC$57.7M+171.1%
NAMSNEWAMSTERDAM PHARMA COMPANY$1.2M

Exited Positions (4)

TickerIssuerNotional
AGIOAGIOS PHARMACEUTICALS INC$35.3M
ETNB89BIO INC$33.9M
ENGNENGENE HOLDINGS INC$14.0M
ELEVELEVATION ONCOLOGY INC$1.7M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
KURAKURA ONCOLOGY INC$28.8M+202.0%+68.2%
VIGLVIGIL NEUROSCIENCE INC$4.1M+121.3%
GLUEMONTE ROSA THERAPEUTICS INC$7.1M+104.7%+421.8%
SEPNSEPTERNA INC$-30.7M+79.3%+487.2%
FDMT4D MOLECULAR THERAPEUTICS IN$-0.1M+70.8%+302.5%
TCRXTSCAN THERAPEUTICS INC$-2.3M+63.6%
PTGXPROTAGONIST THERAPEUTICS INC$51.2M+35.5%+172.2%
ITOSITEOS THERAPEUTICS INC$0.5M+32.3%

Trimmed (5)

TickerIssuerNotionalShares Ξ”Since Filing
XOMAXOMA ROYALTY CORPORATION$-36.0M-17.9%+115.8%
CDTXCIDARA THERAPEUTICS INC$-9.5M-15.4%
GHRSGH RESEARCH PLC$24.6M-15.1%+144.9%
OLMAOLEMA PHARMACEUTICALS INC$-13.4M-7.3%+236.2%
LKFTGALAPAGOS NV$-6.6M-7.3%+21.0%
← Back to Hedge Funds
BVF Partners Q1 2025 13F Filing β€” Holdings & Portfolio | MarketsFN